Opioid Efficacy: A Twin-Study
Information source: Stanford University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Alfentanil (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Stanford University Official(s) and/or principal investigator(s):
David J. Clark, Principal Investigator, Affiliation: Stanford University
David R. Drover, Sub-Investigator, Affiliation: Stanford University
Martin S Angst, Principal Investigator, Affiliation: Stanford University
Summary
Proposed twin study will test to what degree inter-individual differences in pain sensitivity
and amount of pain relief in response to opioid therapy are inherited or alternatively, are
due to environmental factors. This knowledge is important to guide future studies trying to
explain such inter-individual differences. For example, finding that differences are largely
due to environmental factors would discourage genomic studies and emphasize epidemiological
studies.
Clinical Details
Official title: Opioid Efficacy: A Twin-Study
Study design: Other, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study
Primary outcome: To what degree are inter-individual differences in pain sensitivity and pain relief in response to opioid therapy inherited.
Secondary outcome: To what degree are inter-individual differences in other effects of opioid medications inherited.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Monozygotic or dizygotic twins
2. Ages 18-70
Exclusion Criteria:
1. Clinically relevant systemic diseases such as psychiatric, neurological, and
dermatological conditions interfering with the collection and interpretation of study
data
2. History of addiction
3. Allergy to study medication
4. Chronic intake of medication potentially interfering with pain processing (except oral
contraceptives)
5. Intake of over-the-counter analgesics within the two days prior to study
6. Reynaud's disease
7. pregnancy
8. Participation in other study within last 30 days
9. Personnel with direct access to addicting drugs
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
Starting date: May 2008
Last updated: May 5, 2008
|
